ATUL LTD.

Atul Ltd announced that its Board of Directors will convene a meeting on Friday, October 23, 2026. The primary agenda for this meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter and six months ending September 30, 2026. Additionally, the company informed about the closure of its trading window for insiders. The trading window will remain closed from October 01, 2026, to October 25, 2026 (both days inclusive), in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Atul Ltd has announced that its Board of Directors will convene on October 23, 2026. The primary agenda for this meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter and six months ending September 30, 2026. Additionally, the company has informed about the closure of the trading window for its securities, which will be effective from October 1, 2026, to October 25, 2026, inclusive, in compliance with SEBI regulations regarding insider trading.

Atul Ltd has uploaded the Chairman's speech, presentation, and video of the proceedings from its 49th Annual General Meeting (AGM) held on July 31, 2026. These materials are now available on the company's website, providing shareholders and stakeholders with access to key discussions and information presented during the meeting. This move ensures transparency and accessibility of AGM content.

Atul Ltd announced the appointment of Mr. Vinayak Deshpande as an Additional Director and Independent Director, effective August 01, 2026, for a five-year term. This appointment is subject to member approval and follows a recommendation from the Nomination and Remuneration Committee. The Board of Directors took this on record during their meeting today. The company also submitted its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, along with limited review reports. Integrated financial filings in XBRL format are being done separately. The Board meeting commenced at 10:15 am and is continuing for other routine agenda items.

Atul Ltd's Board of Directors has approved a significant capital expenditure of ₹167 crore for a new manufacturing facility. This expansion will introduce a capacity of 1,000 tpa for Mecoprop-p (MCPP-p) and 750 tpa for 2-methyl-4-chlorophenoxyacetic acid (MCPA). The project is slated for completion within 67 weeks. The investment, funded through internal accruals, aims to broaden the company's product portfolio and enhance its market position in Phenoxy herbicides, while also enabling the production of value-added downstream products from o-Cresol and MCA.

Atul Ltd announced the appointment of Mr. Vinayak Deshpande as an Additional Director and Independent Director, effective August 01, 2026, for a five-year term. This appointment is based on the recommendation of the Nomination and Remuneration Committee and is subject to shareholder approval. The company also submitted its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, along with limited review reports. The financial results show a standalone profit after tax of ₹201.03 crore for the quarter ended June 30, 2026, compared to ₹203.84 crore in the previous quarter. The board meeting where these decisions were taken commenced at 10:15 am and was ongoing for other routine agenda items.

ICICI Prudential Mutual Fund, through its various schemes, has acquired 10,140 shares of Atul Limited on July 17, 2026. This acquisition has resulted in the fund's total shareholding crossing the 5% threshold of Atul Ltd's paid-up capital. The fund stated that these acquisitions are for investment purposes and not to gain controlling interest. The total holding now stands at 14,73,240 shares, representing 5.004% of the company's voting capital. The shares were purchased through open market transactions.

Atul Ltd has announced changes in its senior management team, effective July 18, 2026. Dr. Prabhakar Chebiyyam, President of Pharmaceuticals, has retired. Mr. Dhaval Vashi has taken over as Senior Vice President, Pharmaceuticals, becoming a member of the senior management team. Mr. Vinay Desai, Executive Vice President, Technology and Manufacturing, has also joined the senior management team. Dr. Vashi brings approximately 22 years of experience in Business Development and holds postgraduate and doctorate degrees in chemistry. Mr. Desai has about 35 years of experience in manufacturing and technology development, holding a graduate degree in chemical engineering.

Atul Ltd has issued a corrigendum to its Integrated Annual Report 2025-26, filed on July 7, 2026. The company identified typographical errors on page 10, paragraph 9 of the 'Letter to the shareholders' concerning medium-term growth targets. The corrected figures indicate significantly higher planned contributions from existing capacities (revised from ₹436 cr to ~₹900 cr), own expansions (from ₹395 cr to ~₹600 cr), and joint ventures (from ₹40 cr to ~₹300 cr). The specific figure for 'retail' has been removed. The company stated that these corrections do not impact the audited financial statements and that an updated report has been placed on its website and communicated to shareholders.

Atul Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. This report is integrated with the company's annual report for the same period. The filing provides details on the company's corporate identity, operational structure, employee demographics, and market presence. Key business segments include Life Science Chemicals (29% turnover) and Performance and Other Chemicals (70% turnover). The company reported a significant export contribution of 42% to its total turnover and serves approximately 4,000 customers across 32 industries. The report also touches upon employee representation, grievance redressal mechanisms, and CSR applicability.